ASX Share rice
Mon 17 May 2021 - 04:42:am (Sydney)

PXS Share Price

PHARMAXIS LTDPXSPharmaceuticals, Biotechnology & Life Sciences

PXS Company Information

Name:

Pharmaxis Ltd

Sector:

Healthcare

Industry:

Drug Manufacturers-General

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

20 Rodborough Road Frenchs Forest NSW Australia 2086

Phone:

61 2 9454 7200

Full Time Employees:

69

CEO, MD & Director:

Mr. Gary Jonathan Phillips

CFO & Company Sec.:

Mr. David Morris McGarvey BA, CA, CPA

Head of Drug Discovery:

Dr. Wolfgang G. Jarolimek Ph.D., B.Sc. Ph.D.

Alliance Management - Head of Medical & Regulatory Affairs:

Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedSc

Medical Director:

Dr. Brett Charlton Ph.D., MBBS Ph.D.

Gen. Counsel:

Mr. Cameron David Billingsley

Head of Chemistry for Drug Discovery:

Dr. Dieter Hamprecht

Company Overview:

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

PXS Share Price Information

Shares Issued:

452.07M

Market Capitalisation:

$36.62M

Revenue (TTM):

$26.92M

Revenue Per Share (TTM):

$0.07

Earnings per Share:

$0.013

Profit Margin:

0.1861

Operating Margin (TTM):

$-0.06

Return On Assets (TTM):

$-0.12

Return On Equity (TTM):

$1.63

Quarterly Revenue Growth (YOY):

3.943

Gross Profit(TTM):

$11.16M

Diluted Earnings Per Share (TTM):

$0.013

PXS CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-574,000

Change To Liabilities:

$-437,000

Total Cashflow From Investing Activities:

$-574,000

Net Borrowings:

$-2,232,000

Net Income:

$-13,943,000

Total Cash From Operating Activities:

$-13,284,000

Depreciation:

$3.13M

Other Cashflow From Investing Activities:

$-574,000

Change To Inventory:

$-514,000

Change To Account Receivables:

$-288,000

Capital Expenditures:

$259K

PXS Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-13,943,000

Net Income:

$-13,943,000

Gross Profit:

$11.09M

Operating Income:

$-15,894,000

Other Operating Expenses:

$1.65M

Total Revenue:

$12.55M

Cost Of Revenue:

$1.46M

PXS Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$0.94M

Total Liabilities:

$33.99M

Total Stockholder Equity:

$1.43M

Other Current Liabilities:

$2.19M

Total Assets:

$35.42M

Common Stock:

$367.30M

Other Current Assets:

$162K

Retained Earnings:

$-388,187,000

Other Liabilities:

$20.84M

Other Assets:

$1.08M

Cash:

$2.70M

Total Current Liabilities:

$6.83M

Property - Plant & Equipment:

$8.91M

Net Tangible Assets:

$490K

Total Current Assets:

$24.49M

Net Receivables:

$6.94M

Short-Term Investments:

$10.92M

Inventory:

$2.63M

Accounts Payable:

$1.76M

Short-Term Investments:

$10.92

Non Current Liabilities (Other):

$20.72M

Non Current Liabilities Total:

$27.16M

PXS Share Price History

PXS News

18 Mar, 2021
SINGAPORE, March 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PXS). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs. Kathleen spent over 20 years at Merck & Co where she held a number of leadership positions, including Senior Vice President and Head of Worldwide Basic Research, with oversight of all the company’s global research projects, and Senior Vice President, External Discovery and Preclinical Sciences. She was also Chair of the Respiratory Worldwide Business Strategy Team, reporting directly to the Chief Executive Officer. Dr Metters holds a BSc in Biochemistry from the University of Manchester Institute for Science and Technology, and a PhD from Imperial College of Science and Technology in London. Damien Lim, representative of BV Healthcare II Pte Ltd, has transitioned off the board with effect from March 18, 2021, after serving for 10 years. Andrew Howden, Chairman, ASLAN Pharmaceuticals, said, “We are pleased to welcome Dr Metters to ASLAN’s board of directors and look forward to working with her. Kathleen is an accomplished industry leader who brings extensive scientific acumen and global development expertise in immunology. Her insight and experience, combined with that of Dr Neil Graham who recently joined the board, will provide valuable guidance to the management team as ASLAN advances its clinical programs and its pivot to the US. On behalf of the board, I would like to extend our appreciation to Damien Lim for his significant contributions to the growth of the company over the past decade.” Media and IR contacts Emma ThompsonSpurwing CommunicationsTel: +65 6751 2021Email: ASLAN@spurwingcomms.comRobert UhlWestwicke PartnersTel: +1 858 356 5932 Email: robert.uhl@westwicke.com About ASLAN PharmaceuticalsASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.
08 Mar, 2021
Coherent, the provider of lasers and laser-based technologies, deemed the revised buyout offer from II-VI Incorporated as a “Company Superior Proposal.” Per the terms of the revised proposal, the manufacturer of engineered materials and optoelectronic components will pay $170 in cash and 1.0981 shares of II-VI for each share of Coherent (COHR). Coherent intends to terminate the merger agreement with California-based manufacturer and seller of optical and photonic products, Lumentum Holdings (LITE), entered into this January. The company has said the same to Lumentum unless Coherent receives a favorable revised proposal from Lumentum by March 11, 2021. Coherent previously agreed to be acquired for $100 in cash and 1.1851 shares of Lumentum common stock for each share of Coherent. Further, it received two revised proposals from Lumentum. Under the first proposal, each share of Coherent common stock was offered to be exchanged for $175 in cash and 1.0109 shares of Lumentum common stock, while the other proposal offered $170 in cash and 1.0109 shares of Lumentum common stock. Both proposals also included a significantly higher termination fee for accepting competing acquisition proposals. (See Coherent stock analysis on TipRanks) Last month, Coherent also received an unsolicited acquisition proposal from MKS Instruments, in which each share of Coherent common stock was offered to be exchanged for $115 in cash and 0.7473 per share of MKS (MKSI) common stock. Further, MKSI’s revised proposal offered each share of Coherent common stock to be exchanged for $135 in cash and 0.7516 of a share of MKS common stock. Therefore, after a thorough review of all proposals, the company’s board of directors, in consultation with financial and legal advisors, unanimously determined II-VI’s (IIVI) revised acquisition proposal to be the best fit. On Feb. 11, Benchmark Co. analyst Mark Miller downgraded the rating to Hold from Buy on the stock. Meanwhile, the consensus rating on the stock is a Hold. That’s based on unanimous 6 Holds. Looking ahead, the average analyst price target stands at $210.33, putting the downside potential at about 10.6% over the next 12 months. Shares jumped 88.6% over the past year. Related News: Big Lots’ 4Q Profit Beats Analysts’ Estimates As Comparable Sales Rise; Shares Gain 2% Amgen Inks $1.9B Deal To Buy Five Prime Therapeutics; Shares Pop 79% TopBuild Buys Insulation Peer Ozark Foam; Street Sees 16% Upside More recent articles from Smarter Analyst: Paya’s 4Q Revenues Outperform Estimates; Street Is Bullish Monday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6% Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside
Lumentum Holdings Inc. said Monday it received notice from laser technology company Coherent Inc. , which Lumentum has entered into an agreement to acquire, that the unsolicited buyout bid it received from II-VI Inc. was "superior." Lumentum said it will review the II-VI bid, and will have four days to match the rival bid. if the Lumentum-Coherent merger agreement is terminated, Coherent will be required to pay a $217.6 million termination fee. On Feb. 12, II-VI made a $260-per-share cash-and-stock bid to buy Coherent, valuing the company at the time at $6.36 billion, while the cash-and-stock merger agreement with Lumentum announced on Jan. 19 was valued at $5.7 billion. Lumentum's stock gained 0.1% in premarket trading while Coherent's stock rallied 4.4% and II-VI share shed 2.8%. Meanwhile, futures for the S&P 500 fell 0.5%.
Lumentum Holdings Inc. ("Lumentum") today announced that it has received notice from Coherent, Inc. (NASDAQ: COHR) ("Coherent") of its Board of Directors' determination that an unsolicited acquisition proposal from II–VI Incorporated (NASDAQ: IIVI) ("II-VI") to acquire Coherent in a cash and stock transaction constitutes a "Company Superior Proposal" as defined in the previously announced definitive merger agreement with Lumentum entered into on January 18, 2021 and Coherent's intention to terminate such merger agreement.
Coherent, Inc. (NASDAQ: COHR) ("Coherent") today announced that the company's board of directors, in consultation with its financial and legal advisors, has unanimously determined that a revised acquisition proposal Coherent received from II-VI Incorporated (NASDAQ: IIVI) ("II-VI") constitutes a "Company Superior Proposal" under Coherent's pending merger agreement with Lumentum Holdings Inc. (NASDAQ: LITE) ("Lumentum"). Under the terms of II-VI's revised proposal, each share of Coherent common stock would be exchanged for $170.00 in cash and 1.0981 shares of II-VI common stock at the completion of the transaction. Coherent has notifed Lumentum that it intends to terminate their merger agreement unless Coherent receives a revised proposal from Lumentum by 11:59 p.m. Pacific Time on March 11, 2021 that the Coherent board determines to be at least as favorable to Coherent's stockholders from a financial point of view as II-VI's revised proposal, after taking into account all aspects of any such proposal Coherent may receive from Lumentum.
03 Mar, 2021
Lumentum Holdings Inc. ("Lumentum"), a leading provider of VCSEL arrays for 3D sensing and LiDAR applications, today announced new high-power and high-efficiency five and six junction vertical cavity surface-emitting laser (VCSEL) arrays for advanced consumer, automotive LiDAR, and other 3D sensing applications.
02 Mar, 2021
Lumentum Holdings Inc. ("Lumentum") today announced its participation in three key industry events in the next several weeks. At these events, Lumentum will highlight its broad portfolio of advanced solutions for the 3D sensing and laser markets. Additionally, Lumentum thought leaders will present on cutting-edge photonic innovation for next-generation 3D sensing applications in both the automotive and consumer spaces.
23 Feb, 2021
Lumentum Holdings Inc. ("Lumentum") today announced that management is scheduled to participate in the following virtual investor events:
16 Feb, 2021
Coherent, Inc. (NASDAQ: COHR) today announced that its board of directors has determined to engage in discussions with II-VI Incorporated (NASDAQ: IIVI) in response to its unsolicited proposal to acquire Coherent in a transaction where each share of Coherent common stock would be exchanged for $130.00 in cash and 1.3055 shares of II-VI common stock.
14 Feb, 2021
Shares of Coherent jumped nearly 13.8% on Feb. 12 after the provider of lasers and laser-based technologies received a buyout offer from II-VI. The cash and stock deal has a total enterprise value of $6.5 billion. Per the terms of the unsolicited acquisition proposal, the manufacturer of engineered materials and optoelectronic components has proposed to pay $130 in cash and 1.3055 shares of II-VI for each share of Coherent (COHR). The total value, which comes in at $260 per share, represents a 14.6% premium to COHR’s closing price on Feb. 11. Shares of II-VI dropped 9.7% at the close on Feb. 12. After closure, II-VI (IIVI) expects the deal to be accretive to adjusted EPS in the second year. Combined run-rate synergies of $200 million are likely to be realized annually within thirty-six months. Last month, Coherent entered into a cash-stock deal with California-based manufacturer of optical and photonic products, Lumentum Holdings, to be acquired for $100 in cash and 1.1851 shares of Lumentum (LITE) common stock for each share of Coherent. Earlier this week, the company also received an unsolicited acquisition proposal from MKS Instruments, in which each share of Coherent common stock would be exchanged for $115 in cash and 0.7473 per share of MKS (MKSI) common stock. II-VI’s offered price reflects a 24% premium to the implied value of the Lumentum deal and a 9.8% premium to the implied value of MKS Instruments’ buyout proposal. II-VI’s proposal is undergoing Coherent’s board of directors’ review. (See Coherent stock analysis on TipRanks) The pending merger deal with Lumentum along with the proposed offers of MKS and II-VI are all subject to customary closing conditions, which includes U.S. and foreign antitrust approvals as well as stockholder approvals. On Feb. 11, Benchmark Co. analyst Mark Miller downgraded the rating to Hold from Buy, as he is “awaiting the decision on what firm will acquire Coherent.” Meanwhile, the Street’s consensus rating on the stock is a Hold. That’s based on a unanimous 6 Holds. Looking ahead, the average analyst price target stands at $210.33, putting the downside potential at about 18.5% over the next 12 months. Shares have jumped 65.6% over the past year. Related News: Coherent Gets $6B Rival Buyout Offer From MKS; Shares Jump 13.6% Zimmer Biomet To Spin Off Spine and Dental Businesses Electronic Arts To Buy Glu Mobile For $2.1B; Shares Pop 34% More recent articles from Smarter Analyst: Lincoln Electric Posts Better-Than-Expected Quarterly Profit; Street Sees 5% Upside Nvidia’s Proposed Acquisition Of Arm Under Investigation – Report Boeing Accused Of Dragging Its Feet In Response To Fatal Air Crashes – Report Tesla To Establish Manufacturing Plant In India – Report
12 Feb, 2021
Coherent, Inc. (NASDAQ: COHR) ("Coherent") today announced that it has received an unsolicited acquisition proposal from II–VI Incorporated (NASDAQ: IIVI) ("II-VI") to acquire Coherent in a cash and stock transaction. Under the terms of II-VI's proposal, each share of Coherent common stock would be exchanged for $130.00 in cash and 1.3055 shares of II-VI common stock at the completion of the transaction.
Today Lumentum Holdings Inc. (Lumentum), an industry-leading designer and manufacturer of innovative optical and photonic products, announced that their San José headquarters is now powered by San José Clean Energy's (SJCE) 100% renewable energy service, TotalGreen.
11 Feb, 2021
Gary Phillips became the CEO of Pharmaxis Ltd ( ASX:PXS ) in 2013, and we think it's a good time to look at the...
Lumentum Holdings Inc. ("Lumentum") today provided additional perspective on the unsolicited acquisition proposal from MKS Instruments, Inc. (NASDAQ: MKSI) ("MKS") to acquire Coherent, Inc. (NASDAQ: COHR) ("Coherent") in a cash and stock transaction that Lumentum believes faces substantial regulatory hurdles. Lumentum stated:
10 Feb, 2021
Lumentum stock just pulled back to a historically bullish trendline
09 Feb, 2021
Shares of Coherent jumped 13.6% on Feb. 8 after the laser manufacturer announced a buyout bid from MKS Instruments, in a deal valued at $6 billion. According to the unsolicited proposal from MKS, each Coherent (COHR) share would be exchanged for $115 in cash and 0.7473 of MKS share. Shares of MKS dropped 8.1% to $149.24 at the close on Feb. 8. The offer comes after Coherent last month entered into an agreement to be snapped up by Lumentum Holdings (LITE) in a cash and stock deal valued at $5.7 billion. Coherent stated that the company’s management determined that the takeover bid by MKS could lead to a transaction, which could be superior to its pending deal with Lumentum. Coherent plans to enter into another round of discussions with MKS (MKSI), “to further evaluate the comparative benefits and risks of MKS’ proposed transaction relative to Coherent’s pending transaction with Lumentum, including the near and long term financial opportunities of each transaction, the expected completion timing of each transaction, and the closing risks associated with each transaction.” Coherent said that its Board of Directors continues to recommend Lumentum’s acquisition offer to its shareholders. (See Coherent stock analysis on TipRanks) Following the MKS offer, Benchmark Co. analyst Mark Miller assigned a Buy rating and a price target of $226 on Coherent stock. Miller said, “While Lumentum serves complementary markets to Coherent with little overlap, due to some similar markets served by Coherent and MKS Instruments, we believe the deal could face scrutiny from regulators.” The rest of the Street is cautiously bullish about the stock with a Moderate Buy consensus rating. That’s based on 2 analysts recommending a Buy and 6 analysts suggesting a Hold. The average analyst price target of $203.40 implies 7.3% downside potential to current levels. Related News: Cubic Inks $2.8B Buyout Deal With Veritas Capital, Evergreen; Shares Spike 10% Palantir Partners With IBM To Provide AI-Driven Business Solutions Hasbro Hits $1B In Online Sales In 2020 As Demand For Toys Booms More recent articles from Smarter Analyst: Tuesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Take-Two Interactive Sees Lower 4Q Digital Delivery Bookings; Shares Slip 4% Palantir Partners With IBM To Provide AI-Driven Business Solutions Chegg Jumps 5% As Remote Learning Demand Drives Blowout Quarter
08 Feb, 2021
Lumentum Holdings Inc. ("Lumentum") today issued the following statement regarding its definitive agreement to acquire Coherent.
Coherent, Inc. (NASDAQ: COHR) ("Coherent") today announced that it has received an unsolicited acquisition proposal from MKS Instruments, Inc. (NASDAQ: MKSI) ("MKS") to acquire Coherent in a cash and stock transaction. Under the terms of MKS' proposal, each share of Coherent common stock would be exchanged for $115.00 in cash and 0.7473 of a share of MKS common stock at the completion of the transaction, subject to customary closing conditions including receipt of U.S. and foreign antitrust approvals and stockholder approvals.
13 Nov, 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
02 Nov, 2020
FDA Bronchitol approval to generate cash flows in "transformational step" for Pharmaxis